Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation

Incyte ($INCY) announced an update on their ongoing clinical study. Incyte Inc. is moving ahead with a key Phase 3 study called EXCALIBUR-ET2, form...

Incyte’s EXCALIBUR-ET2 Trial Targets a New Edge in Essential Thrombocythemia

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biodesix (BDSX), Incyte (INCY) and Zimmer Biomet Holdings (ZBH). ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Biodesix (BDSX), Incyte (INCY) and Zimmer Biomet Holdings (ZBH)

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Incyte, with a price target of $137.00. According to TipRa...

Mizuho Securities Remains a Buy on Incyte (INCY)

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Incyte, with a price target of $109.00. The company’s s...

RBC Capital Sticks to Their Hold Rating for Incyte (INCY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Centene (CNC), Incyte (INCY) and IQVIA Holdings (IQV...

Analysts Offer Insights on Healthcare Companies: Centene (CNC), Incyte (INCY) and IQVIA Holdings (IQV)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Incyte (INCY) with bullish senti...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY) and Medicus Pharma Ltd (MDCX). Incyte (INCY) Willia...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY) and Medicus Pharma Ltd (MDCX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Baxter International (BAX), Incyte (INCY) and Arge...

Analysts Conflicted on These Healthcare Names: Baxter International (BAX), Incyte (INCY) and Argenx Se (ARGX)

Insiders have been trading these 5 stocks: (($CTAS)), (($KEY)), (($BFLY)), (($CAG)) and (($INCY)). Here is a breakdown of their recent trades and t...

Cintas, KeyCorp, Butterfly Network, Conagra, Incyte Insider Shake-Up

In a report released today, Judah Frommer from Morgan Stanley assigned a Hold rating to Incyte, with a price target of $104.00. Frommer covers the ...

Morgan Stanley Releases a Hold Rating on Incyte (INCY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Halozyme (HALO), Phathom Pharmaceuticals (PHAT) and Incyte (INCY)...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INCY	$124.44	+0.76%	75.72K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INCY	$124.44	+0.8%	75.72K
3
4
5
6

INCY

Get Incyte Corporation Data in Excel

Get Incyte Corporation Data in Excel